ZYXIQ is the OTC ticker for Zynex, Inc., a Colorado-based medical device company specializing in pain management devices and related supplies. Zynex faces severe financial distress and legal challenges following allegations of fraudulent business practices. The company filed for Chapter 11 bankruptcy protection on December 15, 2025 (www.sec.gov), and its stock was delisted from Nasdaq (formerly ticker ZYXI) in late 2025 (www.sec.gov). Investors have launched a securities class action lawsuit alleging that Zynex inflated revenue through improper sales and billing practices, with a lead plaintiff deadline set for April 21, 2026 (www.globenewswire.com). Below, we analyze Zynex’s dividend history, leverage, coverage ratios, valuation, and the key risks and red flags that precipitated its collapse, as well as open questions about its future prospects.
Dividend Policy & History
Zynex has not maintained a consistent dividend program. In its two-decade history as a public company, Zynex paid only two cash dividends – $0.07 per share (declared in 2018, paid January 2019) and $0.10 per share (declared in 2021, paid January 2022) (www.sec.gov). These appear to have been special one-time dividends rather than recurring payouts. Since 2022, the company has not declared further dividends, reflecting a no-current-dividend policy amid its growth efforts and, more recently, financial troubles. With Zynex now in bankruptcy, any near-term dividend is highly unlikely. The current dividend yield is 0%, and any future dividends would depend on a successful reorganization and sustained profitability – both of which are uncertain under the present circumstances (www.sec.gov).
Leverage and Debt Maturities
Zynex’s capital structure became highly leveraged in 2023–2025. In May 2023, the company issued $60 million of 5.00% Convertible Senior Notes due May 15, 2026, raising cash but also adding significant debt (www.sec.gov). These notes were unsecured and scheduled to mature in mid-2026, with semiannual interest payments of ~$1.5 million. Notably, Zynex used much of the proceeds from this convertible offering to repurchase its own stock (including purchases directly from its CEO), instead of bolstering its balance sheet (www.globenewswire.com) (www.globenewswire.com). By late 2025, the company had minimal cash left and defaulted on its interest obligations – in November 2025, Zynex elected to enter a 30-day grace period and did not pay the $1.5 million interest due on the notes (seekingalpha.com). This strategic default signaled a severe liquidity crunch.
Alongside the convertible notes, Zynex had no significant long-term bank loans by 2025, having previously paid off a $16 million term loan used for an acquisition (www.sec.gov). However, upon its Chapter 11 filing in December 2025, Zynex had to secure Debtor-in-Possession (DIP) financing of $22.3 million to fund operations during bankruptcy (www.sec.gov). The DIP loan is a senior secured facility with a short maturity of 105 days from filing (around late March 2026) (www.sec.gov), effectively forcing a rapid reorganization or sale of the company. In summary, Zynex’s debt load – $60 million in notes (now in default) plus $22 million DIP – far exceeds its market capitalization, and key maturities are imminent. Absent a restructuring, these obligations would be unpayable given the company’s cash constraints.
Interest Coverage and Liquidity
Zynex’s ability to service its debt deteriorated dramatically in 2024–2025. The company’s interest coverage ratio dropped to dangerously low levels as earnings declined. In 2024, Zynex recorded interest expense of $2.4 million (mostly from the new notes), up sharply from $1.1 million the prior year (www.sec.gov). Meanwhile, income from operations for 2024 was only $3.6 million (www.sec.gov), implying that operating profit covered interest by a thin 1.5× multiple. By 2025, coverage turned negative – Zynex swung to losses in the first half of 2025 as revenue plunged (discussed below), and it could no longer meet interest payments without additional capital. The company’s cash balance fell from $39.6 million at year-end 2024 to just $13.3 million by September 30, 2025 (seekingalpha.com) (seekingalpha.com), reflecting operating cash burn and heavy share buybacks. Facing a liquidity crisis, management openly acknowledged “current liquidity challenges” and the need to preserve cash (seekingalpha.com). This led to the decision to skip the November 2025 interest payment and negotiate with noteholders for a potential debt restructuring (seekingalpha.com). In short, Zynex’s interest coverage collapsed under the weight of its debt and declining earnings, and the firm ran out of cash – precipitating the bankruptcy filing.
- Predicted IPO date: March 26, 2026
- Options: ARKVX, private fund access code, bonus reports
- Only 500 access codes — first come, first served
Valuation and Stock Performance
Zynex’s valuation has been effectively wiped out by the recent events. The stock (ZYXI on Nasdaq, now ZYXIQ OTC) traded above $8 per share as recently as early 2025 (www.macrotrends.net), reflecting a market capitalization around $250+ million at that time. That valuation already anticipated growth – for reference, Zynex earned only $0.09 EPS in 2024 (www.sec.gov), so the early-2025 price implied a very high P/E multiple (over 80× trailing earnings). However, as operational and legal troubles came to light, shares cratered. In March 2025, Zynex announced a large Q4 2024 revenue shortfall and disclosed that Tricare (its largest payer) had suspended payments, leading the stock to plummet 51% in a single day (seekingalpha.com). After further disclosures in mid-2025 about compliance failures and a leadership shake-up, the stock fell another 45% on August 1, 2025 (seekingalpha.com). By year-end 2025, Zynex closed at $0.13 per share, down 98% for the year (www.macrotrends.net).
As of early 2026, the stock trades around $0.04–$0.05, giving Zynex a de minimis market cap under $5 million (www.macrotrends.net) (www.macrotrends.net). In other words, equity investors are assigning almost no value to the business, anticipating that current shares will be canceled or severely diluted in a restructuring (which management has warned is likely (www.sec.gov)). Zynex’s enterprise value (EV) – roughly $60 million of debt minus scant cash – equates to only ~0.3× its 2024 revenues ($192 million) (www.macrotrends.net). Such a low EV/sales multiple (well below industry peers) underscores the market’s view that the company’s revenue may not be sustainable or profitable going forward. Traditional valuation metrics like price-to-earnings are now meaningless given the company’s negative earnings and bankruptcy status. Overall, Zynex’s valuation collapse from a mid-cap growth stock to essentially a penny stock reflects the severity of its financial and legal predicament.
Key Risks and Red Flags
Zynex’s rapid downfall can be traced to a series of risks and red flags that emerged over the past two years:
– Insurance Dependence & Fraud Allegations: Zynex derived the majority of its revenue from third-party insurance reimbursements, making it vulnerable to payer scrutiny (www.sec.gov) (www.sec.gov). Indeed, the company allegedly engaged in fraudulent billing practices – shipping excessive quantities of products (e.g. disposable electrodes) beyond patients’ needs and billing insurers for them (www.globenewswire.com). This inflated short-term sales but drew the attention of major insurers and regulators. The U.S. military’s health program Tricare, which accounted for roughly 20–25% of Zynex’s revenues, suspended payments to Zynex pending a claims review (seekingalpha.com). Additionally, on August 21, 2023, Travelers Insurance filed suit against Zynex (and certain executives) in California, alleging a fraudulent overbilling scheme involving hundreds of false claims from 2018–2023 and seeking $23 million in damages and penalties (seekingalpha.com). These developments were glaring red flags: they not only threatened a loss of significant revenue (e.g. nearly $49 million collected from Tricare in 2024 could be subject to clawback (www.sec.gov)), but also indicated possible systemic fraud within the company.
– Weak Internal Controls & Aggressive Sales Culture: The class action complaint paints a picture of a management team that prioritized aggressive sales growth over compliance (seekingalpha.com). Zynex reportedly lacked a strong internal control environment, allowing improper practices to continue. For instance, sales representatives may have been incentivized to over-order supplies for patients to boost revenue. Such weaknesses in oversight are a significant risk for any healthcare company reliant on billing integrity. Zynex’s audit committee and board also face scrutiny – they authorized substantial stock repurchases even as operational risks were mounting, including buying back millions of dollars of Zynex stock directly from CEO Thomas Sandgaard in 2023 (www.globenewswire.com). This unusual transaction (effectively cashing out the CEO with company funds) is a corporate governance red flag, suggesting misalignment of management’s interests with shareholders’.
– Management Turnover and Conduct: The upheaval in Zynex’s leadership further signaled distress. In July 2025, the company announced the replacement of founder/CEO Thomas Sandgaard with a new chief executive (Steven Dyson) and the departure of its Chief Financial Officer during that “transformational” quarter (seekingalpha.com). Frequent C-suite changes often foreshadow deeper problems; in Zynex’s case it coincided with the acknowledgment of non-compliance issues. More dramatically, in January 2026 Sandgaard was indicted by a federal grand jury on charges of healthcare and securities fraud (www.sec.gov). The Board immediately removed him from all positions (www.sec.gov). An indicted former CEO is an extreme red flag – strongly validating the earlier fraud allegations. It also raises the prospect of government fines or even criminal penalties against individuals and potentially the company.
– Bankruptcy and Going-Concern Risk: By late 2025, Zynex’s financial situation deteriorated to the point of bankruptcy. The Chapter 11 filing itself is a critical risk factor – it indicates the company was insolvent or unable to meet obligations. Nasdaq’s delisting of the stock on Dec 24, 2025, due to the Chapter 11 proceedings, effectively cut off the company from mainstream equity markets (www.sec.gov). In bankruptcy, there is a high likelihood current shareholders will be wiped out (the company warned that equity holders should expect significant loss under the restructuring plan) (www.sec.gov). The bankruptcy also creates uncertainty for customers and suppliers. Zynex cautioned that operating during Chapter 11 poses substantial risks to its business, including the potential loss of key personnel and further liquidity constraints (www.sec.gov) (www.sec.gov). In short, the going-concern risk for Zynex is very high – without a successful reorganization, the company could face liquidation.
These factors – heavy reliance on reimbursements (and alleged overbilling), compliance failures, management missteps, and financial insolvency – combined to create a perfect storm that has virtually destroyed shareholder value. They are also the basis of the ongoing class action lawsuit, which claims investors were misled about the company’s true financial health and legal compliance (seekingalpha.com).
Open Questions & Outlook
Looking ahead, several critical questions remain open for Zynex investors and stakeholders, even as the class action and bankruptcy process play out:
– What Recovery for Shareholders? Given the Chapter 11 proceedings, a key question is whether existing equity holders will receive anything in a reorganization. Zynex’s disclosures suggest that a cancelation of current shares is likely (www.sec.gov). The company’s liabilities (convertible noteholders, DIP lenders, and possibly insurer claims) far exceed the value of its assets/business under current conditions. Unless a white-knight buyer emerges willing to pay over $60 million, it is hard to envision a recovery for common shareholders. This means the class action lawsuit’s primary avenue for monetary recovery might be through insurance (Directors & Officers liability policies) or personal assets of the defendants, rather than corporate assets.
– Can Zynex Fix Its Business Model? Zynex’s core business of renting/selling electrotherapy devices and supplies to patients is fundamentally tied to insurance reimbursement. A major question is whether the company – under new management – can regain the trust of insurers and regulators. Tricare’s suspension and similar scrutiny from other payers will need to be resolved. Zynex will likely have to implement stringent compliance programs and possibly settle claims (e.g. repay improper billings) to be allowed back into insurer networks. The viability of the company post-bankruptcy hinges on stopping the alleged overbilling practices and operating within normal reimbursement parameters. It remains to be seen if the business can still be profitable under those conditions, or if prior profits were largely driven by unsustainable tactics.
– Outcome of the Restructuring: Another open question is the form and outcome of Zynex’s restructuring. The company has been evaluating strategic alternatives – including raising capital or selling the company – since late 2025 (seekingalpha.com). With the DIP loan’s fast timeline, Zynex may attempt a quick sale of its assets or a debt-for-equity swap that hands control to creditors. Will Zynex emerge as an independent company (perhaps owned by the noteholders), or will it be acquired by a competitor? Any such outcome will influence how the business is run going forward. As of now, no public reorganization plan has been confirmed, so stakeholders are awaiting news on whether Zynex will restructure as a going concern or be broken up.
– Future of New Product Lines: Zynex had been diversifying into new medical device segments – for example, in late 2021 it acquired Kestrel Labs, which developed laser-based pulse oximetry and hemoglobin monitors (www.sec.gov). These products (NiCO™ and HemeOx™) were in development and had not yet generated revenue (www.sec.gov). An open question is whether these pipeline products can salvage Zynex’s future. If brought to market, they could open a new revenue stream (likely selling to hospitals or clinics, possibly with a capital equipment sales model rather than insurance reimbursement). However, the bankruptcy may constrain R&D and commercialization efforts in the near term. It’s uncertain if the new management and eventual owners will choose to invest in these products or perhaps sell those assets to raise cash. The success of such advanced monitoring devices, if pursued, is far from guaranteed but could influence Zynex’s long-term recovery potential.
In conclusion, Zynex’s investors face an extremely uncertain road ahead. The company’s fundamentals have been undermined by alleged misconduct, and it is now navigating bankruptcy court while fighting multiple legal battles. The class action lawsuit (with the April 21, 2026 deadline for investors to join) will seek to prove that Zynex’s management misled shareholders about these risks (seekingalpha.com). But even if investors prevail in court, the actual financial recovery may be limited by the company’s insolvency. For any turnaround to occur, Zynex must restore compliance, settle its disputes with insurers, and restructure its debts – all under new leadership and ownership. Whether it can emerge from Chapter 11 as a viable enterprise (and on what terms) is the paramount question. Stakeholders will be watching developments in the coming months closely, as the answers will determine if Zynex can overcome its troubled legacy or if it will become yet another Chapter 11 casualty in the healthcare sector.
For informational purposes only; not investment advice.